Raleigh Capital Management’s Biogen BIIB Stock Holding History

Raleigh Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-71	Closed	-$10.9K	–	625
2024 Q4	$10.9K	Buy	71 +17	+31%	+$2.87K	﹤0.01%	599
2024 Q3	$10.5K	Sell	54 -41	-43%	-$8.58K	﹤0.01%	583
2024 Q2	$22K	Buy	95 +47	+98%	+$10.2K	0.01%	417
2024 Q1	$10.3K	Buy	48 +18	+60%	+$4.22K	﹤0.01%	558
2023 Q4	$7.76K	Buy	30 +5	+20%	+$1.23K	﹤0.01%	653
2023 Q3	$6.42K	Hold	25	–	–	﹤0.01%	638
2023 Q2	$7.12K	Buy	+25	New	+$7.44K	﹤0.01%	556

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raleigh Capital Management's BIIB Position: Q1 2025 in Review

Raleigh Capital Management sold out of Biogen (BIIB) in Q1 2025, closing a stake of 71 shares — an estimated $10.9K sold.

Raleigh Capital Management first reported a position in BIIB in Q2 2023 and held it in 7 quarters. The position peaked at $22K in Q2 2024. 883 funds tracked by Wall St. Rank hold BIIB as of Q1 2025.

Raleigh Capital Management reported no remaining Biogen position as of Q1 2025 after selling out during the quarter.
Raleigh Capital Management sold 71 Biogen shares in Q1 2025, an estimated $10.9K.
Raleigh Capital Management first reported a position in Biogen in Q2 2023 and held it in 7 quarters.
Raleigh Capital Management's Biogen position peaked at $22K in Q2 2024.
883 funds tracked by Wall St. Rank held Biogen as of Q1 2025.

Based on Raleigh Capital Management's 13F filing for Q1 2025, filed 29 Apr 2025.